| A B C D E F G H I J K L M N O P Q R S T U V W X Y Z # |
Valproic Acid
MessagePerformed in Chemistry
BPMC sends to Sonora Quest Laboratories, test code 2111
BPMC sends to Sonora Quest Laboratories, test code 2111
Test Code
VALP
Alias/See Also
Depakene
2111
2111
CPT Codes
80164
Preferred Specimen
Green Top LiHep, Plasma
BPMC - Red Top, Serum
WMCC - SST
BPMC - Red Top, Serum
WMCC - SST
Other Acceptable Specimens
EDTA, SST, Red
Instructions
For testing performed at Sonora Quest Laboratories, see link below for specimen details, methodology, setup schedule and reference ranges.
Reject Criteria (Eg, hemolysis? Lipemia? Thaw/Other?)
Repeat thaw/freeze cycles
Collected in an outdted/expired tube
Hemolyzed, icteric or lipemic
Contaminated
Collected in an outdted/expired tube
Hemolyzed, icteric or lipemic
Contaminated
FDA Status
FDA Approved
Setup Schedule
Daily, Sunday through Saturday
Report Available
Less than 4 hours
Clinical Significance
Valproic acid (VPA; 2‑propylpentanoic acid; Depakene) is a relatively new anticonvulsant medication which is used chiefly for the treatment of primary and secondary generalized seizures, but is also effective against absence seizures. It is particularly effective in myoclonus, and is the drug of choice in photosensitive epilepsy. Although VPA is used in conjunction with other anti‑epileptic medications, more recent studies have shown benefits of converting treatment to monotherapy with VPA. Also, a growing body of evidence suggests that VPA is useful in treatment of affective disorders; in particular, lithium‑insensitive bipolar disorders.
At therapeutic concentrations, over 90 % of VPA in the circulation is bound to plasma proteins, primarily albumin. Binding is saturable, and at high VPA concentrations, the free fraction increases. Other compounds can compete for VPA binding to albumin; these include salicylic acid and free fatty acids. The concentration of VPA in cerebrospinal fluid is correlated to both the total and unbound concentrations of the drug in plasma.
VPA is converted to a complex mixture of metabolites via β and ω‑oxidation and conjugation. Some metabolites show significant anti‑convulsant activity, while others may be responsible for some of the drug’s toxic side effects.
VPA has the fewest adverse effects of all the widely‑used anti‑epileptic agents. The most common side effects are gastrointestinal disturbances such as nausea and vomiting. Some incidences of tremor, coma or stupor have been noted; these often occur in conjunction with co‑administration of other anti‑epileptic drugs. Rare occurrences of hepatic failure, Reye‑like syndrome, pancreatitis or thrombocytopenia are thought to be individualized reactions unrelated to drug levels. Pharmacokinetics of VPA are highly variable, depending on the form of the drug and route of administration, as well as individual variations in volume of distribution, metabolism and clearance. Moreover, co‑administration of other anti‑epileptic drugs can significantly affect VPA metabolism. Therefore, monitoring VPA concentrations during therapy is essential in order to provide the physician with an indicator for adjusting dosage.
At therapeutic concentrations, over 90 % of VPA in the circulation is bound to plasma proteins, primarily albumin. Binding is saturable, and at high VPA concentrations, the free fraction increases. Other compounds can compete for VPA binding to albumin; these include salicylic acid and free fatty acids. The concentration of VPA in cerebrospinal fluid is correlated to both the total and unbound concentrations of the drug in plasma.
VPA is converted to a complex mixture of metabolites via β and ω‑oxidation and conjugation. Some metabolites show significant anti‑convulsant activity, while others may be responsible for some of the drug’s toxic side effects.
VPA has the fewest adverse effects of all the widely‑used anti‑epileptic agents. The most common side effects are gastrointestinal disturbances such as nausea and vomiting. Some incidences of tremor, coma or stupor have been noted; these often occur in conjunction with co‑administration of other anti‑epileptic drugs. Rare occurrences of hepatic failure, Reye‑like syndrome, pancreatitis or thrombocytopenia are thought to be individualized reactions unrelated to drug levels. Pharmacokinetics of VPA are highly variable, depending on the form of the drug and route of administration, as well as individual variations in volume of distribution, metabolism and clearance. Moreover, co‑administration of other anti‑epileptic drugs can significantly affect VPA metabolism. Therefore, monitoring VPA concentrations during therapy is essential in order to provide the physician with an indicator for adjusting dosage.
Additional Information
Valproic Acid (Depakene) (2111)
